Status:
TERMINATED
carDIo-ttranSSfOrm nucLEar Imaging Study
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Ionis Pharmaceuticals, Inc.
Conditions:
Amyloidosis
Transthyretin Amyloid Cardiomyopathy
Eligibility:
All Genders
60-90 years
Brief Summary
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform cli...
Detailed Description
This is a multicenter trial of 80 subjects enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) who will undergo baseline and follow up Tc-99m PYP to assess for the change in myoc...
Eligibility Criteria
Inclusion
- Patients who were screened and eligible to be enrolled or have been already enrolled in the CARDIO-TTRansform randomized clinical trial (NCT04136171) and have a baseline 99m-technetium pyrophosphate planar and SPECT imaging done within 12 months prior to screening for CARDIO-TTRansform.
- Patients have to meet the inclusion and exclusion criteria of CARDIO-TTRansform trial to be enrolled.
- Patient willing to consent for the study and undergo the study procedures.
Exclusion
- None
Key Trial Info
Start Date :
January 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05259072
Start Date
January 19 2022
End Date
December 30 2023
Last Update
January 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239